Absci (ABSI) Q2 FY26 earnings call

Absci reported positive interim Phase 1 data for ABS-201, highlighting favorable safety and a half-life supporting infrequent dosing, reinforcing confidence in its prolactin receptor mechanism. The company also announced a strategic partnership with Eli Lilly, including a $40 million investment, and completed a $100 million financing, extending its cash runway into H2 2028. This funding supports the advancement of ABS-201 in Pattern Hair Loss and endometriosis, as well as the continued development of its AI-native ATLAS platform.